Bill Gates, the founder of Microsoft and the richest man in the world, has
hinted that he will commit more money to HIV vaccine research in the next few
years. Gates gave £16 million to the International AIDS Vaccine Initiative
earlier this year to support research projects. In an interview with The Sunday
Times last week, Bill Gates Snr, who administers the William H Gates Foundation
for his son, said that a major new programme would be announced within months.
He went on to reveal that Gates plans to donate virtually all of his $65 billion
fortune before he dies to programmes which combat global disease and improve
access to education.
Read the full story at href="http://www.sunday-times.co.uk/news/pages/sti/99/08/01/stifgnusa01012.html?999">http://www.sunday-times.co.uk/news/pages/sti/99/08/01/stifgnusa01012.html?999 color=#0000ff face=Arial size=2>
successful HIV vaccine is to be developed and made available. Read about the
scientific challenges in our section on preventive vaccine research: color=#0000ff face=Arial size=2>
href="http://www.aidsmap.com/heading3.asp?heading2=Preventive+vaccines&newBrowse=true">http://www.aidsmap.com/heading3.asp?heading2=Preventive+vaccines&newBrowse=true face=Arial size=2>
manufacturer, is due to begin trials of a naked DNA vaccine designed to
stimulate strong cytotoxic lymphocyte responses. This approach is thought to be
one of the most promising avenues for HIV vaccine research, and Merck's human
study will provide rapid information on the likely success of the approach.
Unlike anti-retroviral studies which initially took years to prove the value of
combination therapy, early human vaccine studies will be relatively rapid
affairs, because their objective is to show whether the vaccines produce immune
responses. Later studies will take much longer to complete, because they must
show that the vaccine provides long-term protection. size=2>
research at http://www.iavi.org, the website
of the International AIDS Vaccine Initiative.